⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
prnewswire.com
LLY
BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
globenewswire.com
JNJ
LLY
NVO
TEVA
GSK
IFNNY
Liberty All-Star® Growth Fund, Inc. February 2026 Monthly Update
businesswire.com
NVDA
AAPL
GOOGL
MSFT
META
AMZN
CW
OLLI
AVGO
LGN
MPWR
ARTV
ASND
LLY
NVT
CAT
FTAI
LOW
PLTR
TKO
PINS
UNH
Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients
prnewswire.com
KR
LLY
Form Health Joins the Lilly Employer Connect Platform
businesswire.com
LLY
Ovidrel or Ovitrelle (Merck, Eli Lilly) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
MRK
LLY
Ovidrel or Ovitrelle (Merck, Eli Lilly) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
MRK
LLY
Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight USA - English USA - español USA - Deutsch
prnewswire.com
NVS
LLY
AZN
Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable for Millions
prnewswire.com
LLY
U.S. Weight Loss Market Status & Forecast Report 2025-2026: GLP-1 Boom Triggers Major Industry Shift as Medicalized Programs Disrupt the $135 Billion Diet Market
globenewswire.com
WW
NX
HLF
SMPL
NVO
LLY